Brain Cancer Vaccine

"Northwest Biotherapeutics Inc., a Bothell-based biotechnology company, won Swiss approval for its brain-cancer treatment, the first vaccine to harness a patient's immune system to fight the disease.
The product will be produced in the U.S., and made available to patients at treatment centers in Switzerland, Northwest Biotherapeutics said Monday in a prepared statement.
The company is working to win approval in the U.S. and Europe to gain access to the $35 billion market for cancer treatments. In clinical trials, patients treated with DCVax-Brain survived twice as long as those who didn't receive the vaccine, without major side effects, the company said.
"This is an unprecedented product," said Navid Malik, an analyst at Collins Stewart. "The whole field has opened up with this vaccine."
Though the vaccine has only been approved in Switzerland, patients from all over Europe are likely to travel for treatment, Malik said."